Insider trade

CEO sold ~$5.3M of ROIV shares in the open market

Traded Feb 13, 2026 · Filed Feb 19, 2026

Why it stands out

The boss of Roivant Sciences sold $5.3M of Roivant Sciences shares. It happened by itself, for taxes or pay.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

CEO$1M+Pre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$5,298,000

Shares × reported transaction price

Timing vs results

7 days after results of Feb 6, 2026, 48 days before results of Apr 2, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Filing box checked: sold under a Rule 10b5-1 plan

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	+3.5%	+0.7%	+2.8%
30 days	+1.5%	−4.3%	+5.7%
90 days	+17.8%	+8.3%	+9.5%
180 days	+35.8%	+12.1%	+23.7%

Past results only. Not a forecast.

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.35 to $26.69, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.

7mo ago

Derivative exercise or conversion — not an open-market buy.

Automatic sale7mo ago

7mo ago

Derivative exercise or conversion — not an open-market buy.